gemcitabine has been researched along with npi 2358 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, H; Deng, M; Ding, Z; Dou, G; Hou, Y; Li, F; Li, W; Ma, M; Zhao, J | 1 |
| Li, F; Li, W; Liu, Y; Shi, C; Wang, X; Yang, J; Zang, R; Zhao, J; Zhong, L | 1 |
2 other study(ies) available for gemcitabine and npi 2358
| Article | Year |
|---|---|
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Deuterium; Diketopiperazines; Female; Half-Life; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Neoplasms; Protein Binding; Rats; Rats, Wistar; Tissue Distribution | 2018 |
Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Survival; Deoxycytidine; Diketopiperazines; DNA Damage; Drug Synergism; Female; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Rats, Wistar; Tubulin Modulators | 2020 |